昭衍新药(06127.HK)参投长春百克生物科技A股IPO
昭衍新药(06127.HK)公布,以自有资金参与长春百克生物科技股份公司A股IPO的战略投资者配售,公司拟获配120万股,发行价格为每股36.35元人民币,获配金额为4,383.81万元人民币,所获配股票锁定期为12个月。
公司表示,与百克生物已保持多年紧密的合作关系,此次参与战略配售有利於继续深化双方业务合作,双方拟就传染病防治的生物药物(含疫苗)研发、中试、生产、非临床评价、临床服务(包括临床注册、临床运营、临床检测、中心实验室、药物警戒)等领域积极开展战略合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.